APA (7th ed.) Citation

Schumann, K., Mauch, C., Klespe, K., Loquai, C., Nikfarjam, U., Schlaak, M., . . . Posch, C. (2023). Real‐world outcomes using PD‐1 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland. Journal of the European Academy of Dermatology and Venereology, 37(5), 894-906. https://doi.org/10.1111/jdv.18779

Chicago Style (17th ed.) Citation

Schumann, Katharina, et al. "Real‐world Outcomes Using PD‐1 Antibodies and BRAF + MEK Inhibitors for Adjuvant Melanoma Treatment from 39 Skin Cancer Centers in Germany, Austria and Switzerland." Journal of the European Academy of Dermatology and Venereology 37, no. 5 (2023): 894-906. https://doi.org/10.1111/jdv.18779.

MLA (9th ed.) Citation

Schumann, Katharina, et al. "Real‐world Outcomes Using PD‐1 Antibodies and BRAF + MEK Inhibitors for Adjuvant Melanoma Treatment from 39 Skin Cancer Centers in Germany, Austria and Switzerland." Journal of the European Academy of Dermatology and Venereology, vol. 37, no. 5, 2023, pp. 894-906, https://doi.org/10.1111/jdv.18779.